



IFW4 RCE 1626

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/893,585
Filing Date	June 28, 2001
First Named Inventor	Christopher G. Barber, et al.
Art Unit	1626
Examiner Name	Robert Gerstl
Attorney Docket Number	PC10910ARTB

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other _____

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 16-1445
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print IType)	A. Dean Olson	Registration No. (Attorney/Agent)	31,185
Signature		Date	June 4, 2004

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print IType)	Kelly A. Smith	Date	6/4/04
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

06/08/2004 DENHAMU 00000063 161445 09893585

770.00 DA

01 FC:1801



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 4 day of June, 2004.

By

(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Christopher G. Barber, et al. :

Examiner: Kamala Saeed

APPLICATION NO.: 09/893,585 :

FILING DATE: June 28, 2001 :

Group Art Unit: 1626

TITLE: CYCLOPENTYL-SUBSTITUTED
GLUTARAMIDE DERIVATIVES AS
INHIBITORS OF NEUTRAL
ENDOPEPTIDASE

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450,

AMENDMENT ACCOMPANYING RCE

This amendment accompanies the RCE filed herewith and is in reply to the Final Office Action mailed May 16, 2003 concerning the above-identified application and the Notice of Appeal faxed November 14, 2003. A five-month petition for extension of time has been filed May 28, 2004 extending the time for filing the Appeal Brief until June 14, 2004 thus maintaining co-pendency.

The title of the invention is "CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE". The Applicants are Christopher Gordon Barber, Andrew Simon Cook, Graham Nigel Maw, David Cameron Pryde and Alan Stobie.

The correspondence address is:

Gregg C. Benson
Pfizer Inc.
Patent Dept., MS8260-1611
Eastern Point Road
Groton, CT 06340

Please amend the above-identified application as follows: